Nasal administration of anti-CD3 monoclonal antibody (Foralumab) in COVID-19
收藏NIAID Data Ecosystem2026-03-14 收录
官方服务：
资源简介：
In a randomized trial, mild to moderate COVID-19 outpatients received nasal Foralumab (100ug/day) given for 10 consecutive days and were compared to patients that did not receive Foralumab. T cells were used for single cell RNA-sequencing and Bulk-RNAseq
创建时间：
2023-03-01
